Show results for
Refine by
Oncology 66 Of Diagnostic Articles & Analysis
22 news found
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™, first announced in October 2023. Under a definitive partnership agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), SOPHiA GENETICS will ...
A major study published in leading cancer journal, The Lancet Oncology1 have ground-breaking findings on Michelson Diagnostics, the UK based medical device company that use multi-beam Optical Coherence Tomography (‘OCT’) technology, which can transform patient’s treatment and care of basal cell carcinomas (BCC). It was concluded that OCT-guided diagnosis, when compared to a ...
Research, production and marketing are the strengths of our company, and Smiling and Gesanbiotecno projects are an excellent opportunity to enhance the concept of integration between man, environment and technology. In Gesan, R&D department is a fundamental asset for the company’s business and all activities are constantly oriented towards the production and distribution of innovative ...
SYNLAB LABORATORIES TO PERFORM ONCODEEP® BIOMARKER TEST TO HELP DOCTORS DECIDE ON THE MOST EFFECTIVE TREATMENT FOR THEIR CANCER PATIENTS ONCODNA, A GENOMIC AND THERANOSTIC COMPANY SPECIALIZING IN PRECISION MEDICINE FOR THE TREATMENT OF CANCER AND GENETIC DISEASES, ANNOUNCED TODAY A PARTNERSHIP WITH SYNLAB, EUROPE’S LEADING CLINICAL LABORATORY AND MEDICAL DIAGNOSTIC SERVICES PROVIDER. ...
PathPresenter, a pioneer in the development of digital pathology software, and 4D Path Inc., developer of a pan-cancer diagnostic and precision oncology platform enabling AI-based biomarker typing and prognostication from H&E images, are announcing today a global partnership to distribute 4D Q-plasia OncoReader Breast within PathPresenter’s new Clinical Workflow Platform, ClinPx. 4D ...
Transitioning from his role as a 4D Path advisory board member, world-renowned cancer oncologist, health consultant, and entrepreneur Dr. Teich will now serve as 4D Path’s Chief Global Strategist. Dr. Teich’s expertise in facilitating clinical research and supporting innovative, evidence-based health technologies will support 4D Path’s efforts to bring more readily accessible ...
Positron Enters Long Term Cooperation Agreement with Neusoft Medical Systems for the Development and Distribution of Positron’s State of the Art PET/CT System in North America Niagara Falls, NY – January 18, 2022 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a nuclear medicine PET imaging company specializing in the field ...
SeqOne Genomics, a leader in the field of next generation genomics analysis, announces today a distribution partnership with Global Diagnostic Solutions Ltd (GDS) to commercialize SeqOne’s revolutionary genomics analysis software platform in Middle Eastern markets. Under the terms of this agreement, Global Diagnostic Solutions Ltd. will be responsible for the Business Development, ...
DURHAM, N.C. – October 12, 2021 — GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced a new strategic collaboration with Labcorp, a leading global life sciences company, to develop and commercialize new RNA-based gene signatures as diagnostics for people with cancer. This latest collaboration builds on the ...
4D Path, creator of a patented computer-aided pan-cancer diagnostic and precision oncology platform, is pleased to announce that Dr. Craig A. Bunnell, MD, MPH, MBA, has joined the company’s distinguished advisory board. A widely recognized authority in the field of medical oncology, Dr. Bunnell brings a wealth of experience in the treatment and management of breast cancer through clinical ...
Tethis S.p.A, a developer of a novel platform for liquid biopsy testing, announced the appointment of Mr. Bastiaan van der Baan and Mr. Miro Venturi as Independent Members of the Board of Directors. Bastiaan van der Baan, MSc, is currently Chief Clinical and Business Officer at oncology diagnostics test provider Agendia, where he has helped building up the company’s global clinical and ...
Applications HD 3D imaging technology used in the Vimago system provides a solid volume of data, resulting in gapless, non-interpolated imaging data, delivering a 3D map of densities with spatial resolution that is the same in all three dimensions. Hard Tissue Applications: Skulls - sinus, nasal, bulla, ears, brain, oncology, trauma Orthopedics - stifles, elbows, hips, carpus/tarsus, ...
Experienced healthcare industry executive with 35 years of experience Additions to the board of directors to support the company's advancing its lead program, NTX-001, along with its pipeline products Neuraptive Therapeutics, Inc. (Neuraptive), a clinical-stage biotechnology company dedicated to developing novel therapeutics and medical products for the treatment of peripheral nerve ...
Study results presented at ASCO20 showed that the Recurrence Score results on core biopsies predict the likelihood of response to neoadjuvant chemotherapy Results are particularly relevant in the context of the Covid-19 pandemic which is causing the delay of elective surgeries across health systems worldwide Exact Sciences Corp. today announced results from three studies of the Oncotype DX ...
Neuraptive Therapeutics, Inc. (Neuraptive), a clinical-stage biotechnology company dedicated to developing novel therapeutics and medical products for treatment of peripheral nerve injuries (PNI), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its franchise therapeutic product, NTX-001, in the treatment of patients with peripheral nerve ...
Neuraptive Therapeutics Announces FDA Clearance of IND Application for NTX-001, a Novel Approach for the Treatment of Patients with Peripheral Nerve Injuries "We are pleased to have received clearance for the company’s first IND, and are excited to initiate the trial later this year," said Evan Tzanis, Executive Vice President and Head of Research and Development. "We look forward to ...
Lausanne, Switzerland- March 25, 2020 - Debiopharm, a Swiss-based biopharmaceutical company announced today having entered into a worldwide, exclusive license & research agreement with 3B Pharmaceuticals (3BP), a German biotechnology firm, to further the development of their radioligand program, now called Debio 0228, which targets the CAIX (Carbonic Anhydrase 9) enzyme to fight the ...
Program irom Jb rnarmaceuticais Clovis to acquire rights to discovery program for three additional targets for radionuclide therapy Clovis to pay approximately $12 million in upfront payments to 3B Pharmaceuticals Clovis currently planning to file an IND for FAP-targeted radiopharmaceutical therapy in 2H 2020 FAP highly expressed in multiple tumor types; Clovis to pursue broad and ...
Thermo Fisher Scientific today announced an agreement with Eli Lilly and Company for development of a companion diagnostic that will use the U.S Food and Drug Administration-approved, next-generation sequencing-based Oncomine Dx Target Test to identify certain non-small cell lung cancer (NSCLC) and thyroid cancer patients who may be treated with Lilly's investigational therapy, LOXO-292. ...
VisionGate, a clinical stage oncology pharmaceutical and diagnostics company announces two peer-reviewed poster presentations at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC), 23-26 September in Toronto, Canada. These studies demonstrate important new morphometric detection findings of the Cell-CT™ platform and the LuCED® ...